Whilst the very first FDA approved gene therapy was for RPE65-mediated inherited retinal dystrophy [6], evolving strategies are making the technology applicable to more genetically heterogenous common conditions such as glaucoma, diabetic retinopathy and age-related macular degeneration. Here, RPE65 is linked to inherited retinal dystrophy.